Sapporo mentioned ANDA in his post and the link he provided...

Sapporo mentioned ANDA in his post and the link he provided references an ANDA so I interpreted this to mean it was the pathway IRX were pursuing. Fair enough, I misinterpreted and we’re back to square one again to discuss a NDA.

So would it be correct to state that IRX is hoping to apply for new clinical investigation exclusivity? And for what specific pain indication? As for strong IP, no you can’t make that claim at all because IRX doesn’t have any IP at the moment. They have a concept and no patent.

You persist in calling me a troll but fail to answer simple questions. Recently you were trying to tell me that it’s standard practice to borrow against the R&D rebate, which is complete nonsense. Not one company with a robust balance sheet is going to pay away a 20% fee just so they can access the rebate early. IRX did this because they are basically broke.